製藥企業分析報告：Eli Lilly 是由出版商Espicom Business Intelligence在2010年01月所出版的。
這份英文市場調查報告書包含Pages: 142 價格從美金1040起跳。
提供醫療儀器、藥品相關情報，獲得全球高度評價的英國市調公司 Espicom Business Intelligence，調查分析了製藥企業Eli Lilly後，出版了一本綜合報告書"Eli Lilly: Pipeline, Products, Performance, and Potential"。
報告書內容包括：企業策略、產品組合、財務成績、2000年至2010年銷售資料等等，內容綱要摘記如下：
摘要
- 摘要
- 2005年財務成績
- 企業策略
- 產品、研發概要
- 結論
產品組合、研發
- 神經系統
- 內分泌
- 癌症
- 心臟血管
- 抗感染藥物
- 其他
附錄
- 財務成績
- 主要合作
- 基礎建設
- 相關企業、合作夥伴
- 產品索引
Abstract
Eli Lilly is a global manufacturer and distributor of pharmaceutical
therapies for cancer, cardiovascular diseases, central nervous system
ailments, diabetic and endocrine system disorders, and infectious diseases.
Lilly' s top selling product is Zyprexa, an antipsychotic for the treatment of
schizophrenia, with sales in 2008 of over US$4.6 billion.
Lilly has been in operation for 120 years, in which time it has firmly
established itself as a leading pharmaceutical company both domestically in
the US and on a global scale. In recent times, Lilly has been consistently
placed in the top ten research-based companies in terms of pharmaceutical
sales and has developed a competitive product portfolio containing six
blockbuster products with sales in excess of US$1 billion.
Between 2003 and 2006, Lilly made signficant introductions to this portfolio,
with Byetta, Cialis, Alimta, and Cymbalta all making strong entries to their
respective markets. In spite of an incrasingly difficult global pharmaceutical
market, Lilly performed extremely well in fiscal 2007. All reportable segments
and geographic regions recorded double-digit sales growth, whilst company
income also recorded double-digit growth. Lilly' s performance during this
fiscal period stands out amongst many of its competitors and places the
company in good stead for the short- to medium-term.
Potential to maintain Lilly' s recent strong performance comes from its
promising pipeline, which contains a number of novel candidate compounds and
several line extensions for major products. Arzoxifene is in late-stage
clinical trials and would provide a large boost to Lilly' s endocrine and
oncology portfolios, although enzastaurin has recently been found to be
unlikely to achieve its primary endpoint of its Phase III trials, presenting a
major setback. The development of Arxxant currently remains in doubt as Lilly
reviews its options. LY450139 is a landmark product for Lilly, becoming the
first putative disease-modifying drug for Alzheimer' s disease that has reached
the pipeline for a number of years.
This new strategic analysis report Eli Lilly: Pipeline " Products "
Performance " Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- NEUROSCIENCE
- Marketed Products
- Cymbalta/Xeristar
- Zyprexa
- Others
- R&D Projects
- Arxxant
- GRC 6211
- LY2140023
- LY2624803
- mGluR3 antagonist
- mGlu23 prodrug
- Pruvanserin
- Semagacestat
- Solanezumab
- Growth Forecast
- ENDOCRINE DISEASES
- Marketed Products
- Actos
- Byetta
- Evista
- Forteo/Forteo/Forsteo
- Humalog
- Others
- R&D Projects
- LY2189265
- PSN010
- Teplizumab
- TT-223
- Growth Forecast
- ONCOLOGY
- Marketed Products
- Alimta
- Gemzar
- R&D Projects
- Arzoxifene
- Cixutumumab
- Enzastaurin
- IMC-EB10
- LY2181308
- LY2469298
- Necitumumab
- Ramucirumab
- Survivin ASO
- Growth Forecast
- CARDIOVASCULAR
- Marketed Products
- R&D Projects
- Growth Forecast
- OTHERS
- Marketed Products
- R&D Projects
- BAFF antagonist
- INCB28050
- Interleukin-17 (IL-17) antibody
- LY2127399
- LY307161
- LY333531
- OpRA II
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY AGREEMENTS
- Adolor Co
- Alcon
- Ambryx Inc
- Amylin Pharmaceuticals Inc
- Anthera Pharmaceuticals Inc
- Applied NeuroSolutions
- AstraZeneca
- Biosite Diagnostics Incorporated
- Boehringer Ingelheim
- Cardiome Pharma
- Centocor Inc
- Covance Inc
- Cubist Pharmaceuticals Inc
- Daiichi Sankyo
- Deciphera Pharmaceuticals LLC
- Elan Corporation/Amarin Corporation plc
- Emisphere Technologies Inc
- Galapagos NV
- Gastrotech Pharma AS
- Gene Logic Inc
- General Electric/GE Global Research/GE Healthcare
- Glenmark Pharmaceuticals Ltd
- Hutchison MediPharma Ltd
- Implicit Bioscience Ltd
- Incyte Corporation
- International Diabetes Federation
- Isis Pharmaceuticals Inc
- Juvenile Diabetes Research Foundation
- Kowa Pharmaceuticals America Inc
- Ligand Pharmaceuticals Inc
- MacroGenics Inc
- Medarex Inc
- Merck KGaA
- NPIL Research & Development
- NeuroSearch AS
- NOXXON Pharma AG
- PDL BioPharma Inc
- Phytogenics
- Prosidion Ltd
- sanofi-aventis
- Shionogi
- Sirna Therapeutics Inc
- Solvay
- Takeda
- TorreyPines Therapeutics
- Transition Therapeutics Inc
- TransPharma Medical Ltd
- United Therapeutics Ltd
- ViroPharma Incorporated
- Zydus Cadila Ltd
- APPENDIX 3 - INFRASTRUCTURE
- Research And Development Facilities
- Manufacturing Facilities
- APPENDIX 4 - KEY SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
- APPENDIX 5 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Sales By Business Area
- Sales By Geographic Area
- Long-Lived Assets By Geographic Area
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Neuroscience Products, 2008
- Major Endocrine Disease Products, 2008
- Major Oncology Products, 2008
- Major Cardiovascular Products, 2008
INDEX OF CHARTS
- Sales, Costs and Operating Income
- R&D Expenditure and Capital Expenditure
- Sales By Business Area
- Sales By Geographic Area
- Sales of Major Products (2003A-2013E)
- Top Selling Products, 2008
- Cymbalta Sales (2004A-2013E)
- Zyprexa Sales (2003A-2012E)
- Actos Sales (2003A-2013E)
- Byetta Sales (2005A-2013E)
- Evista Sales (2003A-2013E)
- Forteo Sales (2003A-2013E)
- Humalog Sales (2003A-2013E)
- Alimta Sales (2004A-2013E)
- Gemzar Sales (2003A-2013E)
- Arzoxifene Sales (2010E-2014E)
- Enzastaurin Sales (2010E-2014E)
- Cialis Sales (2003A-2013E)
- Effient Sales (2009E-2013E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
